Jessica Molina-Franky
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jessica Molina-Franky has a total of 37 co-authors. Here are the top co-authors by number of shared publications:
- Manuel Elkin Patarroyo
Affiliations Molecular Biology and Immunology Department, Fundación Instituto de Inmunología de Colombia (FIDIC), Bogotá, Colombia, Microbiology Department, Faculty of Medicine, Universidad Nacional de Colombia, Bogotá, Colombia
4 shared publications - Yelson Alejandro Picón-Jaimes
Blanquerna-Faculty of Health Sciences, Ramon Llull University, Barcelona, Spain
4 shared publications - Alida Marcela Gómez Rodríguez
Grupo de Investigación Núcleo, Universidad de Boyacá, Tunja 150007, Colombia
3 shared publications - César Reyes
Fdn Inst Inmunol Colombia FIDIC, Struct Anal Dept, Carrera 50 26-20, Bogota 111321, Colombia
3 shared publications - Markus Kalkum
Department of Immunology and Theranostics, Arthur Riggs Diabetes and Metabolism Research Institute, Beckman Research Institute of the City of Hope, Duarte, CA, United States
3 shared publications - Alfonso J. Rodriguez-Morales
Faculty of Health Sciences, Universidad Científica del Sur, Lima 15067, Peru
2 shared publications
Latest Publications
- Open Access
The reticulocyte restriction: invasion ligand RBP1a of Plasmodium vivax targets human TfR1, prohibitin-2, and basigin
Plasmodium vivax is the most widespread malaria species with predominance in Latin America and Southeast Asia. Devising effective controls against P. vivax infections presents unique challenges due to the parasite’s exclusive invasion of reticulocytes, a transient developmental stage of red blood cells. The ephemeral nature and limited availability of reticulocytes complicate efforts to establish continuous in vitro cultures to study the parasite’s biology and receptor-ligand interactions. Here, the potential of the erythroid cell lines JK-1 and BEL-A as alternatives to reticulocytes was confirmed through successful parasite invasion, marking the first report of P. vivax entry to BEL-A cells. Furthermore, LC-MS was used to quantitatively compare the membrane proteomes of these cell lines with those of reticulocytes and mature erythrocytes. This analysis revealed significant similarities between the membrane proteomes of JK-1, BEL-A, and reticulocytes. In addition to the known Plasmodium receptors, transferrin receptor protein 1 (TfR1 or CD71), CD98hc, and basigin (BSG), potential receptor candidates involved in the parasite’s invasion pathway were identified, including prohibitin-2 (PHB2), CAT-1 (SLC7A1), ATB(0) (SLC1A5), CD36, integrin beta-1 (ITGB1), and Metal transporter CNNM3. Proximity labeling using TurboID enabled the identification of specific interactions between PvRBP1a 158-650 and TfR1, BSG, and prohibitin-2 in the erythroid cell lines. Notably, this is the first report of prohibitin-2 as a receptor for P. vivax . These findings advance the understanding of P. vivax receptor-ligand interactions and underscore the potential of JK-1 and BEL-A cell lines as alternative models for the study of parasite biology. Author Summary: Plasmodium vivax is a major cause of malaria, particularly in Latin America and Southeast Asia. Unlike other malaria parasites, it infects only immature red blood cells (reticulocytes), which are rare and short-lived, making laboratory studies challenging. No continuous in vitro culture system currently exists for P. vivax , limiting research into its invasion mechanisms. In this study, we evaluated two erythroid cell lines, JK-1 and BEL-A, as potential reticulocyte surrogates. We demonstrate that P. vivax can invade both cell types, including BEL-A cells, which had not previously been tested. Comparative analysis revealed key differences in surface protein expression between these cell lines and reticulocytes, compared to mature red blood cells, identifying seven potential parasite-receptor proteins. We further applied a proximity-based protein tagging approach to identify host-parasite interactions mediated by a specific P. vivax protein ligand, RBP1a. This technique revealed a potential role for prohibitin-2, TfR1, and basigin in mediating P. vivax entry into red blood cells by RBP1a binding. The role of prohibitin-2 as a Plasmodium receptor is a novel Discovery. Our results highlight JK-1 and BEL-A cells as valuable tools for P. vivax research and suggest new avenues for investigating host-pathogen interactions, with implications for malaria treatment and vaccine development.
Open AccessThe reticulocyte restriction: invasion ligand RBP1a of Plasmodium vivax targets human TfR1, prohibitin-2, and basigin
Plasmodium vivax is the most widespread malaria species with predominance in Latin America and Southeast Asia. Devising effective controls against P. vivax infections presents unique challenges due to the parasite’s exclusive invasion of reticulocytes, a transient developmental stage of red blood cells. The ephemeral nature and limited availability of reticulocytes complicate efforts to establish continuous in vitro cultures to study the parasite’s biology and receptor-ligand interactions. Here, the potential of the erythroid cell lines JK-1 and BEL-A as alternatives to reticulocytes was confirmed through successful parasite invasion, marking the first report of P. vivax entry to BEL-A cells. Furthermore, LC-MS was used to quantitatively compare the membrane proteomes of these cell lines with those of reticulocytes and mature erythrocytes. This analysis revealed significant similarities between the membrane proteomes of JK-1, BEL-A, and reticulocytes. In addition to the known Plasmodium receptors, transferrin receptor protein 1 (TfR1 or CD71), CD98hc, and basigin (BSG), potential receptor candidates involved in the parasite’s invasion pathway were identified, including prohibitin-2 (PHB2), CAT-1 (SLC7A1), ATB(0) (SLC1A5), CD36, integrin beta-1 (ITGB1), and Metal transporter CNNM3. Proximity labeling using TurboID enabled the identification of specific interactions between PvRBP1a 158-650 and TfR1, BSG, and prohibitin-2 in the erythroid cell lines. Notably, this is the first report of prohibitin-2 as a receptor for P. vivax . These findings advance the understanding of P. vivax receptor-ligand interactions and underscore the potential of JK-1 and BEL-A cell lines as alternative models for the study of parasite biology. Author Summary: Plasmodium vivax is a major cause of malaria, particularly in Latin America and Southeast Asia. Unlike other malaria parasites, it infects only immature red blood cells (reticulocytes), which are rare and short-lived, making laboratory studies challenging. No continuous in vitro culture system currently exists for P. vivax , limiting research into its invasion mechanisms. In this study, we evaluated two erythroid cell lines, JK-1 and BEL-A, as potential reticulocyte surrogates. We demonstrate that P. vivax can invade both cell types, including BEL-A cells, which had not previously been tested. Comparative analysis revealed key differences in surface protein expression between these cell lines and reticulocytes, compared to mature red blood cells, identifying seven potential parasite-receptor proteins. We further applied a proximity-based protein tagging approach to identify host-parasite interactions mediated by a specific P. vivax protein ligand, RBP1a. This technique revealed a potential role for prohibitin-2, TfR1, and basigin in mediating P. vivax entry into red blood cells by RBP1a binding. The role of prohibitin-2 as a Plasmodium receptor is a novel Discovery. Our results highlight JK-1 and BEL-A cells as valuable tools for P. vivax research and suggest new avenues for investigating host-pathogen interactions, with implications for malaria treatment and vaccine development.
- Open Access
Mass Spectrometric Detection of Formaldehyde-Crosslinked PBMC Proteins in Cell-Free DNA Blood Collection Tubes
Streck tubes are commonly used to collect blood samples to preserve cell-free circulating DNA. They contain imidazolidinyl urea as a formaldehyde-releasing agent to stabilize cells. We investigated whether the released formaldehyde leads to crosslinking of intracellular proteins. Therefore, we employed a shotgun proteomics experiment on human peripheral blood mononuclear cells (PBMCs) that were isolated from blood collected in Streck tubes, EDTA tubes, EDTA tubes containing formaldehyde, or EDTA tubes containing allantoin. The identified crosslinks were validated in parallel reaction monitoring LC/MS experiments. In total, we identified and validated 45 formaldehyde crosslinks in PBMCs from Streck tubes, which were also found in PBMCs from formaldehyde-treated blood, but not in EDTA- or allantoin-treated samples. Most were derived from cytoskeletal proteins and histones, indicating the ability of Streck tubes to fix cells. In addition, we confirm a previous observation that formaldehyde crosslinking of proteins induces a +24 Da mass shift more frequently than a +12 Da shift. The crosslinking capacity of Streck tubes needs to be considered when selecting blood-collection tubes for mass-spectrometry-based proteomics or metabolomic experiments.
Open AccessMass Spectrometric Detection of Formaldehyde-Crosslinked PBMC Proteins in Cell-Free DNA Blood Collection Tubes
Streck tubes are commonly used to collect blood samples to preserve cell-free circulating DNA. They contain imidazolidinyl urea as a formaldehyde-releasing agent to stabilize cells. We investigated whether the released formaldehyde leads to crosslinking of intracellular proteins. Therefore, we employed a shotgun proteomics experiment on human peripheral blood mononuclear cells (PBMCs) that were isolated from blood collected in Streck tubes, EDTA tubes, EDTA tubes containing formaldehyde, or EDTA tubes containing allantoin. The identified crosslinks were validated in parallel reaction monitoring LC/MS experiments. In total, we identified and validated 45 formaldehyde crosslinks in PBMCs from Streck tubes, which were also found in PBMCs from formaldehyde-treated blood, but not in EDTA- or allantoin-treated samples. Most were derived from cytoskeletal proteins and histones, indicating the ability of Streck tubes to fix cells. In addition, we confirm a previous observation that formaldehyde crosslinking of proteins induces a +24 Da mass shift more frequently than a +12 Da shift. The crosslinking capacity of Streck tubes needs to be considered when selecting blood-collection tubes for mass-spectrometry-based proteomics or metabolomic experiments.
- Open Access
- 30 September 2023
- Published by MDPI AG in Tropical Medicine and Infectious Disease
- Vol. 8 (10) , 463
Relationship between Duffy Genotype/Phenotype and Prevalence of Plasmodium vivax Infection: A Systematic Review
The Duffy protein, a transmembrane molecule, functions as a receptor for various chemokines and facilitates attachment between the reticulocyte and the Plasmodium Duffy antigen-binding protein. Duffy expression correlates with the Duffy receptor gene for the chemokine, located on chromosome 1, and exhibits geographical variability worldwide. Traditionally, researchers have described the Duffy negative genotype as a protective factor against Plasmodium vivax infection. However, recent studies suggest that this microorganism’s evolution could potentially diminish this protective effect. Nevertheless, there is currently insufficient global data to demonstrate this phenomenon. This study aimed to evaluate the relationship between the Duffy genotype/phenotype and the prevalence of P. vivax infection. The protocol for the systematic review was registered in PROSPERO as CRD42022353427 and involved reviewing published studies from 2012 to 2022. The Medline/PubMed, Web of Science, Scopus, and SciELO databases were consulted. Assessments of study quality were conducted using the STROBE and GRADE tools. A total of 34 studies were included, with Africa accounting for the majority of recorded studies. The results varied significantly regarding the relationship between the Duffy genotype/phenotype and P. vivax invasion. Some studies predominantly featured the negative Duffy genotype yet reported no malaria cases. Other studies identified minor percentages of infections. Conversely, certain studies observed a higher prevalence (99%) of Duffy-negative individuals infected with P. vivax. In conclusion, this systematic review found that the homozygous Duffy genotype positive for the A allele (FY*A/*A) is associated with a higher incidence of P. vivax infection. Furthermore, the negative Duffy genotype does not confer protection against vivax malaria.
- 30 September 2023
- Published by MDPI AG in Tropical Medicine and Infectious Disease
- Vol. 8 (10) , 463
Open AccessRelationship between Duffy Genotype/Phenotype and Prevalence of Plasmodium vivax Infection: A Systematic Review
The Duffy protein, a transmembrane molecule, functions as a receptor for various chemokines and facilitates attachment between the reticulocyte and the Plasmodium Duffy antigen-binding protein. Duffy expression correlates with the Duffy receptor gene for the chemokine, located on chromosome 1, and exhibits geographical variability worldwide. Traditionally, researchers have described the Duffy negative genotype as a protective factor against Plasmodium vivax infection. However, recent studies suggest that this microorganism’s evolution could potentially diminish this protective effect. Nevertheless, there is currently insufficient global data to demonstrate this phenomenon. This study aimed to evaluate the relationship between the Duffy genotype/phenotype and the prevalence of P. vivax infection. The protocol for the systematic review was registered in PROSPERO as CRD42022353427 and involved reviewing published studies from 2012 to 2022. The Medline/PubMed, Web of Science, Scopus, and SciELO databases were consulted. Assessments of study quality were conducted using the STROBE and GRADE tools. A total of 34 studies were included, with Africa accounting for the majority of recorded studies. The results varied significantly regarding the relationship between the Duffy genotype/phenotype and P. vivax invasion. Some studies predominantly featured the negative Duffy genotype yet reported no malaria cases. Other studies identified minor percentages of infections. Conversely, certain studies observed a higher prevalence (99%) of Duffy-negative individuals infected with P. vivax. In conclusion, this systematic review found that the homozygous Duffy genotype positive for the A allele (FY*A/*A) is associated with a higher incidence of P. vivax infection. Furthermore, the negative Duffy genotype does not confer protection against vivax malaria.
- Open Access
- 14 July 2023
- Published by MDPI AG in Preprints.org
Relationship between Duffy Genotype/Phenotype and Prevalence of Plasmodium vivax Infestation: A Systematic Review
The Duffy protein, a transmembrane molecule, functions as a receptor for various chemokines and facilitates attachment between the reticulocyte and the Plasmodium Duffy antigen-binding protein. Duffy expression correlates with the Duffy receptor gene for the chemokine, located on chromosome 1, and exhibits geographical variability worldwide. Traditionally, researchers have described the Duffy negative genotype as a protective factor against phenotypic malaria expression. However, recent studies suggest this microorganism's evolution potentially diminishes this protective effect. Nevertheless, there is currently insufficient global data to demonstrate this phenomenon. This study aimed to evaluate the relationship between the Duffy genotype/phenotype and the prevalence of Plasmodium vivax infection. The protocol for the systematic review was registered in PROSPERO as CRD42022353427 and involved reviewing published studies from 2012 to 2022. Medline, Web of Science, Scopus, and Scielo databases were consulted. Assessments of study quality were conducted using the STROBE and GRADE tools. A total of 34 studies were included, with Africa accounting for most recorded studies. The results varied significantly regarding the relationship between the Duffy genotype/phenotype and Plasmodium vivax invasion. Some studies predominantly featured the negative Duffy genotype yet reported no malaria cases. Other studies identified minor percentages of infections. Conversely, certain studies observed a higher prevalence (99%) of Duffy-negative individuals infected with Plasmodium vivax. In conclusion, no evidence of a gender-specific distribution of malaria between Duffy-negative men and women was found. However, evidence supports that the homozygous Duffy genotype positive for the A allele (FY*A/*A) is associated with a higher incidence of Plasmodium infection. Furthermore, the negative Duffy genotype does not confer protection against this disease.
- 14 July 2023
- Published by MDPI AG in Preprints.org
Open AccessRelationship between Duffy Genotype/Phenotype and Prevalence of Plasmodium vivax Infestation: A Systematic Review
The Duffy protein, a transmembrane molecule, functions as a receptor for various chemokines and facilitates attachment between the reticulocyte and the Plasmodium Duffy antigen-binding protein. Duffy expression correlates with the Duffy receptor gene for the chemokine, located on chromosome 1, and exhibits geographical variability worldwide. Traditionally, researchers have described the Duffy negative genotype as a protective factor against phenotypic malaria expression. However, recent studies suggest this microorganism's evolution potentially diminishes this protective effect. Nevertheless, there is currently insufficient global data to demonstrate this phenomenon. This study aimed to evaluate the relationship between the Duffy genotype/phenotype and the prevalence of Plasmodium vivax infection. The protocol for the systematic review was registered in PROSPERO as CRD42022353427 and involved reviewing published studies from 2012 to 2022. Medline, Web of Science, Scopus, and Scielo databases were consulted. Assessments of study quality were conducted using the STROBE and GRADE tools. A total of 34 studies were included, with Africa accounting for most recorded studies. The results varied significantly regarding the relationship between the Duffy genotype/phenotype and Plasmodium vivax invasion. Some studies predominantly featured the negative Duffy genotype yet reported no malaria cases. Other studies identified minor percentages of infections. Conversely, certain studies observed a higher prevalence (99%) of Duffy-negative individuals infected with Plasmodium vivax. In conclusion, no evidence of a gender-specific distribution of malaria between Duffy-negative men and women was found. However, evidence supports that the homozygous Duffy genotype positive for the A allele (FY*A/*A) is associated with a higher incidence of Plasmodium infection. Furthermore, the negative Duffy genotype does not confer protection against this disease.
- Open Access
- 22 November 2022
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (23) , 14528
The Black Box of Cellular and Molecular Events of Plasmodium vivax Merozoite Invasion into Reticulocytes
Plasmodium vivax is the most widely distributed malaria parasite affecting humans worldwide, causing ~5 million cases yearly. Despite the disease’s extensive burden, there are gaps in the knowledge of the pathophysiological mechanisms by which P. vivax invades reticulocytes. In contrast, this crucial step is better understood for P. falciparum, the less widely distributed but more often fatal malaria parasite. This discrepancy is due to the difficulty of studying P. vivax’s exclusive invasion of reticulocytes, which represent 1–2% of circulating cells. Its accurate targeting mechanism has not yet been clarified, hindering the establishment of long-term continuous in vitro culture systems. So far, only three reticulocyte invasion pathways have been characterised based on parasite interactions with DARC, TfR1 and CD98 host proteins. However, exposing the parasite’s alternative invasion mechanisms is currently being considered, opening up a large field for exploring the entry receptors used by P. vivax for invading host cells. New methods must be developed to ensure better understanding of the parasite to control malarial transmission and to eradicate the disease. Here, we review the current state of knowledge on cellular and molecular mechanisms of P. vivax’s merozoite invasion to contribute to a better understanding of the parasite’s biology, pathogenesis and epidemiology.
- 22 November 2022
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (23) , 14528
Open AccessThe Black Box of Cellular and Molecular Events of Plasmodium vivax Merozoite Invasion into Reticulocytes
Plasmodium vivax is the most widely distributed malaria parasite affecting humans worldwide, causing ~5 million cases yearly. Despite the disease’s extensive burden, there are gaps in the knowledge of the pathophysiological mechanisms by which P. vivax invades reticulocytes. In contrast, this crucial step is better understood for P. falciparum, the less widely distributed but more often fatal malaria parasite. This discrepancy is due to the difficulty of studying P. vivax’s exclusive invasion of reticulocytes, which represent 1–2% of circulating cells. Its accurate targeting mechanism has not yet been clarified, hindering the establishment of long-term continuous in vitro culture systems. So far, only three reticulocyte invasion pathways have been characterised based on parasite interactions with DARC, TfR1 and CD98 host proteins. However, exposing the parasite’s alternative invasion mechanisms is currently being considered, opening up a large field for exploring the entry receptors used by P. vivax for invading host cells. New methods must be developed to ensure better understanding of the parasite to control malarial transmission and to eradicate the disease. Here, we review the current state of knowledge on cellular and molecular mechanisms of P. vivax’s merozoite invasion to contribute to a better understanding of the parasite’s biology, pathogenesis and epidemiology.
- Open Access
- 1 January 2022
- Published by Universidad de Santander - UDES in Revista Cuidarte
- Vol. 13 (1)
Validación Cuestionario FSI-10 y grado de satisfacción con dispositivos de inhaloterapia
Introducción. El tratamiento farmacológico de la EPOC se realiza progresiva y escalonadamente de acuerdo a la gravedad y puede ser modificado en función de la respuesta al mismo, por lo cual se han desarrollado instrumentos con el fin de evaluar la satisfacción del paciente con los distintos sistemas de inhalación; sin embargo, estos instrumentos han sido diseñados en su mayoría para pacientes con Asma. Objetivo. Validar el instrumento FSI-10 y determinar el nivel de satisfacción de los dispositivos de inhaloterapia en pacientes con EPOC. Materiales y métodos. Estudio transversal prospectivo y de validación de contenido, muestreo probabilístico estratificado con afijación proporcional; población de 337 pacientes con diagnóstico EPOC de la provincia Centro del departamento de Boyacá, Colombia. Se evaluó el cuestionario FSI-10 mediante la prueba de esfericidad de Bartlett, Kaiser-Meyer-Olkin y alfa de Cronbach. Resultados. La prueba de esfericidad resultó estadísticamente significativa, sugiriendo la existencia de correlaciones dentro de la matriz de diez preguntas. La variación total explicable de las diez preguntas que corresponden a la versión del FSI 10 dio cuenta del 81 % de variabilidad. Los pacientes evaluados reportaron un nivel de satisfacción entre bastante a algo con los dispositivos de inhaloterapia. Conclusiones. Las propiedades psicométricas permiten su utilización en la satisfacción del paciente con dispositivos de medicación inhalada, sin presentar diferencias en la comprensión y teniendo resultado fiables. La satisfacción con los dispositivos de inhaloterapia no es muy alta en la mayoría de la población evaluada.
- 1 January 2022
- Published by Universidad de Santander - UDES in Revista Cuidarte
- Vol. 13 (1)
Open AccessValidación Cuestionario FSI-10 y grado de satisfacción con dispositivos de inhaloterapia
Introducción. El tratamiento farmacológico de la EPOC se realiza progresiva y escalonadamente de acuerdo a la gravedad y puede ser modificado en función de la respuesta al mismo, por lo cual se han desarrollado instrumentos con el fin de evaluar la satisfacción del paciente con los distintos sistemas de inhalación; sin embargo, estos instrumentos han sido diseñados en su mayoría para pacientes con Asma. Objetivo. Validar el instrumento FSI-10 y determinar el nivel de satisfacción de los dispositivos de inhaloterapia en pacientes con EPOC. Materiales y métodos. Estudio transversal prospectivo y de validación de contenido, muestreo probabilístico estratificado con afijación proporcional; población de 337 pacientes con diagnóstico EPOC de la provincia Centro del departamento de Boyacá, Colombia. Se evaluó el cuestionario FSI-10 mediante la prueba de esfericidad de Bartlett, Kaiser-Meyer-Olkin y alfa de Cronbach. Resultados. La prueba de esfericidad resultó estadísticamente significativa, sugiriendo la existencia de correlaciones dentro de la matriz de diez preguntas. La variación total explicable de las diez preguntas que corresponden a la versión del FSI 10 dio cuenta del 81 % de variabilidad. Los pacientes evaluados reportaron un nivel de satisfacción entre bastante a algo con los dispositivos de inhaloterapia. Conclusiones. Las propiedades psicométricas permiten su utilización en la satisfacción del paciente con dispositivos de medicación inhalada, sin presentar diferencias en la comprensión y teniendo resultado fiables. La satisfacción con los dispositivos de inhaloterapia no es muy alta en la mayoría de la población evaluada.
- 11 August 2020
- Published by Universidad de Boyacá in Revista Investigación en Salud Universidad de Boyacá
- Vol. 7 (2)
Proteínas homólogas de unión a reticulocitos de Plasmodium falciparum involucradas en el proceso de invasión al eritrocito: Revisión de la literatura
Introducción. La malaria es uno de los mayores retos de salud pública a nivel mundial, es causada principalmente por los parásitos Plasmodium falciparum y Plasmodium vivax. Durante el proceso de invasión, se encuentran involucradas las proteínas homólogas de unión a reticulocitos de Plasmodium falciparum PfRH1, PfRH2a, PfRH2b, PfRH4 y PfRH5, que tras su unión a receptores específicos de membrana permiten la invasión del merozoíto al eritrocito. Objetivo. Compilar y resumir las características moleculares y estructurales de las interacciones entre las proteínas pertenecientes a la familia de proteínas homólogas de unión a reticulocitos de Plasmodium falciparum y los receptores expresados en la célula del hospedero. Método. Revisión descriptiva sobre las proteínas homólogas de unión a reticulocitos de Plasmodium falciparum involucradas en el proceso de invasión al eritrocito. Esta revisión, incluye literatura publicada hasta el año 2020 en bases de datos electrónicas especializadas en investigación biomédica. Se encontraron 105 documentos, de los cuales se seleccionaron 70 y se excluyeron 11 por no presentar los criterios de inclusión, analizando un total de 59 referencias. Conclusión. La invasión del merozoíto es mediada por interacciones específicas de los ligandos de las familias EBL y PfRH. La unión de las proteínas PfRH1 y PfRH2b a sus receptores en el eritrocito, dan lugar a la liberación de la proteína EBL-175, que junto con PfRH4 median la formación de una unión estrecha entre el parásito y los glóbulos rojos, permitiendo así, la unión de la proteína PfRH5 a basigina y la entrada del parásito a la célula del hospedero.
- 11 August 2020
- Published by Universidad de Boyacá in Revista Investigación en Salud Universidad de Boyacá
- Vol. 7 (2)
Proteínas homólogas de unión a reticulocitos de Plasmodium falciparum involucradas en el proceso de invasión al eritrocito: Revisión de la literatura
Introducción. La malaria es uno de los mayores retos de salud pública a nivel mundial, es causada principalmente por los parásitos Plasmodium falciparum y Plasmodium vivax. Durante el proceso de invasión, se encuentran involucradas las proteínas homólogas de unión a reticulocitos de Plasmodium falciparum PfRH1, PfRH2a, PfRH2b, PfRH4 y PfRH5, que tras su unión a receptores específicos de membrana permiten la invasión del merozoíto al eritrocito. Objetivo. Compilar y resumir las características moleculares y estructurales de las interacciones entre las proteínas pertenecientes a la familia de proteínas homólogas de unión a reticulocitos de Plasmodium falciparum y los receptores expresados en la célula del hospedero. Método. Revisión descriptiva sobre las proteínas homólogas de unión a reticulocitos de Plasmodium falciparum involucradas en el proceso de invasión al eritrocito. Esta revisión, incluye literatura publicada hasta el año 2020 en bases de datos electrónicas especializadas en investigación biomédica. Se encontraron 105 documentos, de los cuales se seleccionaron 70 y se excluyeron 11 por no presentar los criterios de inclusión, analizando un total de 59 referencias. Conclusión. La invasión del merozoíto es mediada por interacciones específicas de los ligandos de las familias EBL y PfRH. La unión de las proteínas PfRH1 y PfRH2b a sus receptores en el eritrocito, dan lugar a la liberación de la proteína EBL-175, que junto con PfRH4 median la formación de una unión estrecha entre el parásito y los glóbulos rojos, permitiendo así, la unión de la proteína PfRH5 a basigina y la entrada del parásito a la célula del hospedero.
- Open Access
- 2 July 2020
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 21 (13) , 4729
Hotspots in Plasmodium and RBC Receptor-Ligand Interactions: Key Pieces for Inhibiting Malarial Parasite Invasion
Protein-protein interactions (IPP) play an essential role in practically all biological processes, including those related to microorganism invasion of their host cells. It has been found that a broad repertoire of receptor-ligand interactions takes place in the binding interphase with host cells in malaria, these being vital interactions for successful parasite invasion. Several trials have been conducted for elucidating the molecular interface of interactions between some Plasmodium falciparum and Plasmodium vivax antigens with receptors on erythrocytes and/or reticulocytes. Structural information concerning these complexes is available; however, deeper analysis is required for correlating structural, functional (binding, invasion, and inhibition), and polymorphism data for elucidating new interaction hotspots to which malaria control methods can be directed. This review describes and discusses recent structural and functional details regarding three relevant interactions during erythrocyte invasion: Duffy-binding protein 1 (DBP1)–Duffy antigen receptor for chemokines (DARC); reticulocyte-binding protein homolog 5 (PfRh5)-basigin, and erythrocyte binding antigen 175 (EBA175)-glycophorin A (GPA).
- 2 July 2020
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 21 (13) , 4729
Open AccessHotspots in Plasmodium and RBC Receptor-Ligand Interactions: Key Pieces for Inhibiting Malarial Parasite Invasion
Protein-protein interactions (IPP) play an essential role in practically all biological processes, including those related to microorganism invasion of their host cells. It has been found that a broad repertoire of receptor-ligand interactions takes place in the binding interphase with host cells in malaria, these being vital interactions for successful parasite invasion. Several trials have been conducted for elucidating the molecular interface of interactions between some Plasmodium falciparum and Plasmodium vivax antigens with receptors on erythrocytes and/or reticulocytes. Structural information concerning these complexes is available; however, deeper analysis is required for correlating structural, functional (binding, invasion, and inhibition), and polymorphism data for elucidating new interaction hotspots to which malaria control methods can be directed. This review describes and discusses recent structural and functional details regarding three relevant interactions during erythrocyte invasion: Duffy-binding protein 1 (DBP1)–Duffy antigen receptor for chemokines (DARC); reticulocyte-binding protein homolog 5 (PfRh5)-basigin, and erythrocyte binding antigen 175 (EBA175)-glycophorin A (GPA).
- 18 May 2020
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 527 (4) , 1021-1026
Malaria: Paving the way to developing peptide-based vaccines against invasion in infectious diseases
- 18 May 2020
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 527 (4) , 1021-1026
Malaria: Paving the way to developing peptide-based vaccines against invasion in infectious diseases
- Open Access
- 25 March 2020
- Published by Universidad de Boyacá in Revista Investigación en Salud Universidad de Boyacá
- Vol. 7 (1) , 118-136
Avances en el desarrollo de una vacuna efectiva contra Cryptosporidium parvum: una revisión de la literatura
Introducción. Cryptosporidium parvum es un parásito zoonótico altamente prevalente, asociado a enfermedad diarreica en población inmunocomprometida, niños y terneros menores de 30 días. Esta infección puede ocasionar deshidratación, alteración del estado de conciencia, retraso en el desarrollo global y, en algunos casos, la muerte del paciente. A pesar de la alta prevalencia de C. parvum, no existen medicamentos completamente efectivos ni una vacuna aprobada para prevenir dicha enfermedad. Objetivo. Realizar una revisión de la literatura sobre candidatos vacunales contra C. parvum. Método. Revisión documental mediante la búsqueda de la literatura de los últimos 20 años, disponible en las bases de datos PubMed central, WEB OF SCIENCE, Embase, REDALYC y LILACS. Resultados. Las vacunas atenuadas, recombinantes, basadas en ADN, expresadas en vectores bacterianos y sintéticas han mostrado resultados prometedores en la inducción de inmunogenicidad contra los antígenos de C. parvum, siendo el antígeno de superficie de 15 kilodaltons de Cryptosporidium parvum (cp15), el antígeno inductor de una mejor respuesta inmune celular y humoral en el modelo murino estudiado. Conclusión. Se espera que la incorporación de nuevas técnicas para la selección de antígenos promisorios y la ejecución de una gran cantidad de ensayos in vivo, favorezcan el desarrollo de una vacuna totalmente efectiva contra C. parvum. Aunque el camino para lograr este objetivo será largo y difícil, se convierte en la mejor alternativa para controlar una de las enfermedades de interés en salud pública, con mayor impacto en la población inmunocomprometida.
- 25 March 2020
- Published by Universidad de Boyacá in Revista Investigación en Salud Universidad de Boyacá
- Vol. 7 (1) , 118-136
Open AccessAvances en el desarrollo de una vacuna efectiva contra Cryptosporidium parvum: una revisión de la literatura
Introducción. Cryptosporidium parvum es un parásito zoonótico altamente prevalente, asociado a enfermedad diarreica en población inmunocomprometida, niños y terneros menores de 30 días. Esta infección puede ocasionar deshidratación, alteración del estado de conciencia, retraso en el desarrollo global y, en algunos casos, la muerte del paciente. A pesar de la alta prevalencia de C. parvum, no existen medicamentos completamente efectivos ni una vacuna aprobada para prevenir dicha enfermedad. Objetivo. Realizar una revisión de la literatura sobre candidatos vacunales contra C. parvum. Método. Revisión documental mediante la búsqueda de la literatura de los últimos 20 años, disponible en las bases de datos PubMed central, WEB OF SCIENCE, Embase, REDALYC y LILACS. Resultados. Las vacunas atenuadas, recombinantes, basadas en ADN, expresadas en vectores bacterianos y sintéticas han mostrado resultados prometedores en la inducción de inmunogenicidad contra los antígenos de C. parvum, siendo el antígeno de superficie de 15 kilodaltons de Cryptosporidium parvum (cp15), el antígeno inductor de una mejor respuesta inmune celular y humoral en el modelo murino estudiado. Conclusión. Se espera que la incorporación de nuevas técnicas para la selección de antígenos promisorios y la ejecución de una gran cantidad de ensayos in vivo, favorezcan el desarrollo de una vacuna totalmente efectiva contra C. parvum. Aunque el camino para lograr este objetivo será largo y difícil, se convierte en la mejor alternativa para controlar una de las enfermedades de interés en salud pública, con mayor impacto en la población inmunocomprometida.